Trial Profile
An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and a Comparison to Subcutaneous (SC) Injection in Human Immunodeficiency Virus (HIV) Subjects Diagnosed With Kaposi Sarcoma (KS)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tc 99m tilmanocept (Primary) ; Tc 99m tilmanocept (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions
- Sponsors Navidea Biopharmaceuticals
- 14 Jul 2020 Status changed from active, no longer recruiting to completed.
- 11 Mar 2020 According to a Navidea Biopharmaceuticals media release, the company is currently compiling results.
- 05 Mar 2020 Planned End Date changed from 1 Sep 2019 to 1 Mar 2020.